AR125321A2 - Compuesto cristalino, método de preparación y composición que lo comprende - Google Patents
Compuesto cristalino, método de preparación y composición que lo comprendeInfo
- Publication number
- AR125321A2 AR125321A2 ARP220100895A ARP220100895A AR125321A2 AR 125321 A2 AR125321 A2 AR 125321A2 AR P220100895 A ARP220100895 A AR P220100895A AR P220100895 A ARP220100895 A AR P220100895A AR 125321 A2 AR125321 A2 AR 125321A2
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline compound
- preparation
- composition including
- compound
- crystalline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Un compuesto cristalino que tiene la fórmula (1). También se divulgan métodos de elaboración y composiciones que lo comprenden. Reivindicación 1: Un compuesto cristalino caracterizado porque tiene la fórmula (1). Reivindicación 35: Un método para transformar el compuesto cristalino de la reivindicación 11 en el compuesto cristalino de la reivindicación 19, caracterizado porque el método comprende la cristalización desde una forma solubilizada del Compuesto 1 o la conversión en suspensión. Reivindicación 38: Una composición farmacéutica caracterizada porque comprende una forma cristalina de cualquiera de las reivindicaciones precedentes, y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125321A2 true AR125321A2 (es) | 2023-07-05 |
Family
ID=59772778
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102330A AR109393A1 (es) | 2016-08-23 | 2017-08-23 | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
| ARP220100895A AR125321A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
| ARP220100894A AR125320A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102330A AR109393A1 (es) | 2016-08-23 | 2017-08-23 | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100894A AR125320A2 (es) | 2016-08-23 | 2022-04-08 | Compuesto cristalino, método de preparación y composición que lo comprende |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (es) |
| EP (2) | EP3504189A1 (es) |
| JP (3) | JP2019524853A (es) |
| KR (2) | KR20190040043A (es) |
| CN (4) | CN115974955A (es) |
| AR (3) | AR109393A1 (es) |
| AU (3) | AU2017315682B2 (es) |
| BR (1) | BR112019003637A2 (es) |
| CA (1) | CA3034262A1 (es) |
| CL (2) | CL2019000477A1 (es) |
| CO (1) | CO2019002596A2 (es) |
| EA (1) | EA201990565A1 (es) |
| EC (1) | ECSP19020141A (es) |
| IL (2) | IL315950A (es) |
| JO (1) | JOP20190022B1 (es) |
| MA (1) | MA46042A (es) |
| MX (2) | MX393240B (es) |
| MY (1) | MY200479A (es) |
| PE (2) | PE20190915A1 (es) |
| PH (1) | PH12019500375A1 (es) |
| SG (1) | SG11201901445TA (es) |
| TW (3) | TWI904593B (es) |
| WO (1) | WO2018039378A1 (es) |
| ZA (1) | ZA201901051B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2766380B1 (en) | 2011-10-14 | 2019-04-24 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| TW202426002A (zh) | 2014-10-16 | 2024-07-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CN115974955A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| WO2019055764A1 (en) * | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| EP3806863A1 (en) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| WO2020155057A1 (zh) * | 2019-01-31 | 2020-08-06 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| PH12021553005A1 (en) | 2019-05-31 | 2023-08-14 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| IL296645A (en) | 2020-03-25 | 2022-11-01 | Sage Therapeutics Inc | Use of agents for treatment of respiratory conditions |
| BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| WO2022072620A1 (en) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Methods of treating fibromyalgia with neuroactive steroids |
| WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| BR112023018607A2 (pt) * | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| MX2023012728A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| KR20240006026A (ko) | 2021-04-29 | 2024-01-12 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| PE20240780A1 (es) | 2021-07-28 | 2024-04-17 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| ES2356306T3 (es) | 2002-02-08 | 2011-04-06 | Ono Pharmaceutical Co., Ltd. | Compuestos y fármacos derivados de piperidina que contienen los compuestos como principio activo. |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| EP2766380B1 (en) | 2011-10-14 | 2019-04-24 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| SG11201504848QA (en) | 2012-12-18 | 2015-07-30 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| EP4144746A1 (en) | 2014-05-29 | 2023-03-08 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| TW202426002A (zh) | 2014-10-16 | 2024-07-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| CN108135838A (zh) | 2015-10-16 | 2018-06-08 | 马瑞纳斯制药公司 | 包含纳米粒的可注射神经类固醇制剂 |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| CN115974955A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| JP7196157B2 (ja) | 2017-08-31 | 2022-12-26 | 武田薬品工業株式会社 | Ｃｎｓ状態の治療 |
| IL303250A (en) | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| WO2019055764A1 (en) | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| MA51316A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter les troubles du snc |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| EP3806863A1 (en) | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| EP4321519A3 (en) | 2018-10-12 | 2024-05-01 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| EP4606812A3 (en) | 2018-10-19 | 2025-10-15 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| US20220372067A1 (en) | 2018-12-21 | 2022-11-24 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| PH12021553005A1 (en) | 2019-05-31 | 2023-08-14 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| MX2021015848A (es) | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del snc. |
| CA3143509A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI896548B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| CN114761019A (zh) | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| CN115551874A (zh) | 2020-03-18 | 2022-12-30 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
| IL296645A (en) | 2020-03-25 | 2022-11-01 | Sage Therapeutics Inc | Use of agents for treatment of respiratory conditions |
| IL299176A (en) | 2020-06-24 | 2023-02-01 | Sage Therapeutics Inc | Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds |
| BR112023000990A2 (pt) | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| IL303101A (en) | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| BR112023018607A2 (pt) | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| IL307516A (en) | 2021-04-12 | 2023-12-01 | Sage Therapeutics Inc | Tremor treatment |
| MX2023012728A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| KR20240006026A (ko) | 2021-04-29 | 2024-01-12 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
-
2017
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en not_active Ceased
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 TW TW113108231A patent/TWI904593B/zh active
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 IL IL315950A patent/IL315950A/en unknown
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125321A2 (es) | Compuesto cristalino, método de preparación y composición que lo comprende | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX376106B (es) | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b. | |
| IL247227A0 (en) | -2,4disubstituted phenylene-1,5-diamine derivatives and their uses, and pharmaceutical compounds and compounds obtained from them | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| HK1255500A1 (zh) | 氧固醇及其使用方法 | |
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| EA201990455A1 (ru) | КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| TN2017000031A1 (en) | Imidazopyridazine compounds | |
| WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| MX2017015812A (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| WO2016116882A3 (en) | Novel compositions of carfilzomib | |
| PH12019500822B1 (en) | Crystalline forms of eravacycline | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| MY200499A (en) | Sulfonamide pharmaceutical composition | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |